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PatientsatlatestageParkinson’sdisease(PD)developseveralmotorandnonmotorcomplications,whichdramaticallyimpairtheir
quality of life. These complications include motor ﬂuctuations, dyskinesia, unpredictable or absent response to medications, falls,
dysautonomia,dementia,hallucinations,sleepdisorders,depression,andpsychosis.Thetherapeuticmanagementshouldbedriven
by the attempt to create a balance between beneﬁt and side eﬀects of the pharmacological treatments available. Supportive care,
including physical and rehabilitative interventions, speech therapy, occupational therapy, and nursing care, has a key role in the
latestageofdisease.InthisreviewwediscusstheseveralcomplicationsexperiencedbyadvancePDpatientsandtheirmanagement.
The importance of an integrative approach, including both pharmacological and supportive interventions, is emphasized.
1.Introduction
Advanced Parkinson’s disease (PD), stage 4 or 5 of the
Hoehn and Yahr Scale [1], is characterized by very limited
mobility without assistance, severe motor deﬁcits, risk of
falls, and cognitive and psychotic problems. The mean time
from disease onset to wheelchair-dependence is estimated at
14years [2], although about a third of patients seem to have
a relatively milder disease and remain stable for many years
[3]. With the advent of the L-Dopa and other dopaminergic
treatments, the progression of PD has become markedly
slower. However, over the years treatment loses its eﬃcacy,
while a number of complications, such as motor ﬂuctuations
and dyskinesia, develop, probably due to the progressive
loss of dopaminergic neurons and their striatal and cortical
connections [4]. These complications are observed in 50% of
patients after 5 years of disease and in 80% of patients after
10yearsoftreatment[5,6].However,theresponsetoL-Dopa
therapy predictability decreases over the years.
While worsening of motor function and the drug-
inducedmotorcomplicationsrepresentsamajorchallengein
patients with mid to advanced disease, in the advanced stage
of PD the most troublesome and distressful complications
are usually in the area of non-motor symptoms, including
psychiatric and cognitive disorders, autonomic disturbances,
and sleep disorders that signiﬁcantly increase the need for
supportive.Thesesymptomsarefrequentlyneglectedinclin-
ical practice due to limited consultation time, perception of
the patient and caregivers that their symptoms are unrelated
to the disease, or insuﬃcient awareness of the clinicians who
generally focus the consultation towards motor symptoms
[7].
Psychosis and dementia are frequent and share a com-
mon pathophysiology in a signiﬁcant proportion of patients
[8, 9], where the impact on patients and family is variable.
Dementia is associated with reduction in quality of life [10]
andpatientlifespan[11],psychosisisariskfactorfornursing
home placement [12], and both are important sources of
caregiver distress [13].
Management of motor and non-motor complications
should be tailored to the individual patient. This implies
a careful assessment of whether the symptom is a side eﬀect
of the medications or is related to the progression of the
disease. In advanced disease, patients may also experience an
enhanced sensitivity to small changes in L-Dopa or become
more prone to adverse reactions to antiparkinsonian drugs.
Proper supporting care becomes increasingly important
in advanced PD. Rehabilitative and support services for2 Parkinson’s Disease
patients and family also become key interventions as the
disease reaches its more debilitating stages and pharmaco-
l o g i c a lo rs u r g i c a lt r e a t m e n tb e c o m e sl e s sr e l e v a n t .
In this article we discuss the spectrum of the motor
and non-motor complications seen in advanced stage PD
and present an evidence-based review of current therapeutic
options in the management of these complications.
2.Motor Disability
PD is deﬁned as advanced when the patient is severely
disabled. As per Hoehn and Yahr classiﬁcation, patients in
stage4arestillabletowalkandstand unassisted, butthey are
markedly incapacitated in their ability to perform activities
of daily living (ADL). Patients in stage 5 are conﬁned to bed
or wheelchair unless aided.
Many patients in advanced stage range from stage 4 to
5 during the day because of the inconsistent and limited
response to their medications.
Even when patients are still able to ambulate without
assistance, limited motor ability due to marked bradykinesia
and inability to perform ﬁne and alternate movements lead
them to dependency in ADLs, being unable to provide for
basic personal care like dressing, bathing, and often feeding.
Advanced patients are frail individuals exposed to high
risk of several unfavorable circumstances during daily activi-
ties, like falls.
The incidence of falls in advanced PD is high (40–70%)
[14], even when patients are optimally medicated. Falls in
advanced PD occur because of very unstable gait, loss of
center of gravity, poor balance, orthostatic hypotension,
side eﬀects of medications like antidepressants and benzo-
diazepines, and disturbances of posture like camptocormia
or retropulsion. Falls lead to injuries and fracture that
further reduce patient independence and increase the risk of
nursing home admission. Patients with previous falls often
develop fear of falling which further limits their mobility,
contributing to increased weakness and deterioration.
Because of the devastating consequences, an assessment
of falls risk should be taken in all advanced PD patients.
A combination of both disease-speciﬁc and balance- and
mobility-related measures is necessary to accurately predict
falls in patients with PD [15].
Treatment of falls implies a complex approach aimed at
reducing all the potential risk factors, muscle strengthening,
range of motion exercise and balance, and postural control
training.
Although there is still insuﬃcient evidence for eﬀective
prevention of falls, exercise interventions have shown to
be eﬀective at improving physical functioning, leg strength,
balance, and walking [16]. Thus, physical interventions
should be emphasized in advanced stages of disease, par-
ticularly as falls are currently not well addressed either by
pharmacotherapy nor by subthalamic nucleus deep-brain
stimulation (DBS) surgery.
The neuroanatomical substrates of posture and gait are
poorly understood but a number of important observations
suggest a major role for the pedunculopontine nucleus
and adjacent areas in the brainstem. A recent double-
blinded study reported a signiﬁcant reduction in falls in
the on and oﬀ medication states both at 3 and 12months
after pedunculopontine nucleus DBS as captured in the
Uniﬁed Parkinson’s Disease Rating Scale part II scores in six
advanced Parkinson’s disease patients with signiﬁcant gait
and postural abnormalities [17].
It has to be noted, however, that advanced patients are
at high risk of short- and long-term complications from
the DBS procedure, and surgical treatment is generally con-
traindicated in these patients. Furthermore, literature on
pedunculopontine nucleus DBS is still limited, and long-
term follow-up studies investigating safety and eﬃcacy are
unavailable.
3. Motor Complications
Long-termmotorcomplicationsofPDareduetodurationof
disease and treatment, and to cumulative intake of L-Dopa,
with several central and peripheral mechanisms involved.
The progressive degeneration of the nigrostriatal dopamin-
ergic transmission results in fewer and fewer terminals
capable of taking up exogenously administered L-Dopa and
converting it to dopamine for subsequent storage and release
[6]. Unlike early and mid-stage PD patients advanced-
and end-stage patients experience an enhanced sensitivity
to small changes in plasma L-dopa levels [18, 19], that
narrowthetherapeuticwindowandnegativelyimpactmotor
function.
3.1. Wearing-Oﬀ,O n - O ﬀ Fluctuations, and Management Str-
ategies. “Wearing-oﬀ” refers to the recurrence of motor and
non-motor symptoms preceding the scheduled dose of L-
Dopa,whiletheon-oﬀﬂuctuationsaresuddenunpredictable
shifts between “well-” or “over-” treated status (on) and an
undertreatedstatewithsevereParkinsonismsymptoms(oﬀ).
“Wearing-oﬀ”a n do n - o ﬀ ﬂuctuations overlap in ad-
vanced patients.
“Wearing-oﬀ” is a direct consequence of the nonphysi-
ological, pulsatile dopaminergic stimulation, and its occur-
rence is generally predictable following the L-Dopa admin-
istration with progressive therapeutic window progressively
narrowing over the years.
A plethora of sensory, psychiatric, and autonomic
symptoms may be associated with the motor ﬂuctuation.
Patients, indeed, may present with paresthesia, pain, anxiety,
shortness of breath, sweating, and other symptoms that may
not be recognized as part of the L-Dopa response pattern
[20].
Management strategy for “wearing-oﬀ” phenomena is
focused on prolonging the eﬀect of individual L-Dopa doses
without increasing the pulsatile dopaminergic stimulation.
Strategies include fragmentation of dosing, with more
frequent administration of lower doses, and use of COMT
inhibitor (entacapone and tolcapone), MAO inhibitor (sele-
giline and rasagiline), and use of dopamine agonists.
Adjunctive therapy with a COMT inhibitor extends the
duration of the L-Dopa eﬀect, hence ameliorating wearingParkinson’s Disease 3
oﬀ, by blocking the COMT enzyme in the peripheral
catabolism of L-Dopa. Potential adverse event, however,
may arise from the COMT inhibitors. Increasing synaptic
dopamine levels may also be associated with dyskinesia and
increased L-Dopa toxicity leading to worsening of dementia
and psychosis.
Fragmentation of oral therapy, with L-Dopa adminis-
tered up to 6-7 times a day at about 3-hour intervals,
is a commonly used and eﬀective strategy [21]. However,
lowering individual doses of L-Dopa may increase the risk
of occasional drug failure or delayed response.
Substitution of regular with controlled-release L-dopa
preparations may be particularly reasonable in end-stage
patients [22], but the available extended release formulations
are not always aﬀective and reliable.
The use of dopamine-agonists (DAs), although theoret-
ically useful in regulating ﬂuctuations by direct stimulation
of the postsynaptic receptors, is generally contraindicated
in late-stage disease in order to avoid hallucinations and
psychosis, and worsening of autonomic dysfunction.
The main challenge in controlling the on-oﬀ response is
to improve the “on” time without increasing the dyskinesia.
In very late-stage PD this can be achieved using liquid
formulations of L-Dopa [23], which can be prepared by dis-
solving ten 25/100mg standard-release carbidopa/levodopa
tablets and 2g of ascorbic acid in 1 L of tap water [24].
Gastrointestinal dysfunction, with erratic gastric empty-
ing worsening over the years, is a common cause of poor
absorption of L-Dopa in PD. There is no gastric absorption
of L-Dopa, indeed; so gastric emptying and transit via the
pyloric sphincter are critical factors for regular intestinal
absorption [25].
The liquid eﬀervescent levodopa formulation of melev-
odopa (methyl-ester levodopa) plus carbidopa is a prodrug
with a high solubility (about 250times more than L-Dopa)
in small volume of water, and it is able to reach quickly
the small intestine where it is absorbed in a more regular
and rapid way compared to solid formulations [26]. One
clinical advantage of this formulation is that it avoids erratic
absorption and the related unpredictability in the plasma
L-Dopa concentration curve [27]. The drug is approved in
certain European countries and currently under phase II
investigation in the US.
Continuous infusion of levodopa/carbidopa gel through
portable duodenal systems (Duodopa) using percutaneous
endoscopic gastrostomy (PEG) can be a practical alternative
[28, 29]. The infusion provides constant plasma levodopa
concentration and continuous dopamine availability and
receptor stimulation. This solution may be particularly
reasonable in very advance patients with severe dysphagia,
as the PEG may also be used for nutrition. Intrajejunal
L-dopa/carbidopa gel infusion is eﬀective in reducing oﬀ
time, severity and duration of dyskinesia in advanced PD
[30, 31]. Most importantly, a recent multicenter study
demonstrated that intrajejunal L-dopa/carbidopa infusion
provides a beneﬁcial eﬀect on several nonmotor complica-
tions, including cardiovascular, gastrointestinal, and urinary
symptoms, sleep/fatigue, attention/memory, and pain [32].
Adverse event can occur, however, from the procedure
or from the dislocation or occlusion of the intestinal tube.
Advanced patients may also experience local complications
at the site of entry, particularly inﬂammation and infections.
Apomorphine subcutaneous infusion is also an eﬀective
optionforpatientswithsevereﬂuctuationspoorlycontrolled
by oral treatment [33]. Apomorphine infusion is often
limited by the development of skin reaction at the site of
injections after few years of treatment.
3.2. Dyskinesias. Dyskinesias are involuntary choreiform,
twisting and turning movements invariably occurring in
patients undergoing long-term L-Dopa treatment. Dyskine-
sias usually occur in “on” state, as chorea, myoclonus or
dystonic movement. In end-stage patients dyskinesia may
appear in oﬀ state as dystonic posture, especially in the
lower limbs. Oﬀ dystonia is generally most troublesome
upon morning awakening but in advanced disease may
also develop complex twisting dystonic movements during
the day. Because of the narrow therapeutic window at this
stage it is also not uncommon for patients to experience
diphasic dyskinesia. These are usually repetitive alternating
movements occurring at the beginning as well as at the end
of the interval between two L-Dopa doses [34].
Management of dyskinesias implies detailed understand-
ing of the L-Dopa cycle.
The most common approach is to lower the single L-
Dopa dose. Controlled-release levodopa may worsen dysk-
inesias, especially later in the day due to cumulative eﬀect.
Amantadine in doses between 100mg and 400mg can be
eﬀective, but side eﬀects are frequent in more advanced
patients and should be carefully monitored. These include
edema, livedo reticularis, and confusional state or hallucina-
tions and psychosis.
Clozapine,anatypicaldopaminereceptorantagonist,has
beenfoundtobeeﬀectiveinreducingdyskinesiainadvanced
patients [35, 36], and it may be particularly useful when
hallucinations are also present. Advanced patients, however,
are particularly prone to develop agranulocitosis, with high
risks of infections, and thus the white cell count should be
regularly monitored.
Recent evidence suggests that memantine is also eﬀective
in reducing dyskinesia when other options are contraindi-
cated [37, 38].
Despite limited evidence-based data high-frequency sub-
talamic DBS (DBS-HFS) has been shown by several reports
to be surgically safe and able to produce improvements in
dopaminergic drug-sensitive symptoms and reductions in
subsequent drug dose and dyskinesias are well documented.
However, the procedure is associated with adverse eﬀects,
mainly neurocognitive, with side-eﬀects created by spread
of stimulation to surrounding structures, depending on the
precise location of electrodes. The occurrence of cognitive
complications limits the motor improvements induced by
STN-HFS to a short period of time, because patients’ quality
of life is greatly impaired by the progressing cognitive
disorder. In late stage of disease the rate of patients eligible
for surgical treatment of PD is extremely low, due to age
and general debilitation that signiﬁcantly increase the risks
of short- and long-term complications.4 Parkinson’s Disease
3.3. Drug Failure Response. As the disease progresses, the
eﬃcacy of L-Dopa progressively decreases and patients may
not respond at all to administered doses. This phenomenon
is more pronounced later during the day and may be
related to poor gastric emptying and insuﬃcient intestinal
absorption. Domperidone is an eﬀective option, where
available. The neutral aromatic amino acids contained in
dietary proteins may compete with L-Dopa for intestinal
absorptionandtransportacrosstheblood-brainbarrier,thus
limiting its eﬃcacy and being responsible for the occurrence
of motor ﬂuctuations. Low-protein dietary regimens with
protein redistribution by shifting protein intake to the
evening are an eﬀective strategy to ameliorate the response
to L-Dopa. Low-protein products designed for chronic renal
failure patients are also a safe, well-tolerated, and useful
option for end-stage patients [39].
4. Nonmotor Complications
The neuroanatomical and neurochemical substrates of the
majority of non-motor symptoms are still unclear, although
the concept of Parkinson’s disease as a six-stage pathological
process introduced by Braak and collegues [40]p r o v i d e d
critical information to understand the physiopathology
of several nonmotor symptoms, such as sleep disorder,
autonomic dysfunction, and visual hallucinations.
Several studies have shown that non-motor symptoms
impact signiﬁcantly on quality of life and institutionalization
is greater than for the motor symptoms [41, 42]; so in
recent year attention was focused on the development of
measures speciﬁcally designed to recognize and quantify
these symptoms in advanced patients, and they are now also
widely used in the clinical trials.
The development of clinical measures useful in recog-
nizing and quantifying these symptoms deeply improved the
clinical care as well as the clinical trials.
The Non-Motor Symptoms Scale, for instance, is a 30-
itemscaleforassessmentofninedimensions(cardiovascular,
sleep/fatigue, mood/cognition, perceptual problems, atten-
tion/memory, gastrointestinal, urinary, sexual function, and
miscellany), that has proven to be a valid, reproducible, and
accurate tool in rating severity and frequency of non-motor
symptoms in PD [43, 44].
4.1. Dementia. Community-based studies of dementia in
patients with PD have reported a prevalence between 28%
and 44%, with longitudinal studies estimating that dementia
occurs in up to 75% of patients [45]. The pattern of deﬁcits
is similar to dementia with Lewy bodies and diﬀers from that
in Alzheimer’s disease for the predominant involvement of
executive,visuospatial,andattentiondysfunctionandforthe
presence of cognitive ﬂuctuations [46–49].
The cognitive symptoms are a consequence of dopamin-
ergic depletion [50] in the corticostriatal loop and of
dysfunction of the cholinergic system [51]. Serotoninergic
andnoradrenergicmechanismsmayalsobeinvolved,though
their role is not well deﬁned.
Dopaminergic replacement does not lead to cogni-
tive improvement or may even worsen it, but choliner-
gic enhancement can instead be helpful. Cholinesterase
inhibitors,infact,maybeeﬀectiveinamelioratingcognition,
but their tolerability seems variable due to peripheral
cholinergic adverse eﬀects and in some case can worsen
motor functions. Rivastigmine seems the most useful agent
[52], while more controversial is the beneﬁt produced by
donepezil [53, 54].
Avoiding the medications that can possibly worsen
dementia, like anticholinergics and DA-agonists, as well as
maintaining L-Dopa at the lowest eﬀective doses, is certainly
a key strategy to contain confusion, hallucinations, and
psychosis in advanced patients [55].
4.2. Hallucinations and Psychosis. Behavioral disorders, and
especially hallucinations, illusions, and other psychotic
symptoms, are also frequent in advanced PD with frequency
rates ranging from 25 to 30%. Resembling very closely those
seen in dementia with Lewy bodies, psychotic symptoms
in PD are represented by delusions (false and ﬁxed beliefs
maintained despite evidence to the contrary) and, particular,
hallucinations (abnormal perceptions that can involve any
sensory modality in the absence of a physical stimulus).
Visual hallucinations, simple or complex in form, are the
most common psychotic symptom in advanced PD patients,
typically occurring in dim surrounding, but often occurring
through the entire day in late-stage patients [56].
A range of factors contributes to the development of
hallucinations and psychosis in PD, including intrinsic
pathology and dopaminergic replacement therapy.
In the treatment of these complications the ﬁrst step
should always be to evaluate the role of drugs that can
potentially induce or worsen psychosis, such as amantadine,
anticholinergics, COMT-inhibitors, and DA-agonists. These
drugsshouldbetaperedoﬀ,balancingtheeﬀectonpsychosis
with worsening of motor function.
All precipitating events, like urinary and pulmonary
infections, cerebrovascular events, and metabolic dysfunc-
tions, should be also carefully investigated and treated if
possible, as even mild metabolic imbalance or infection can
profoundly aﬀect the development of psychotic symptoms.
Decreasing the dose of L-Dopa should also be considered
when severe psychosis persists, even though this action could
worsen parkinsonim.
All traditional antipsychotic drugs, such as haloperi-
dol, aripriprazole, and chlorpromazine, should be avoided
because of the high sensitivity of PD patients to the motor
adverse eﬀects induced through potent antagonisms of
D2receptors.
Clozapine and quetiapine are the only two newest
antipsychotic that should be considered atypical, thus safe in
PD, due to their predominant aﬃnity for D1 and D4receptor
and low aﬃnity for D2 receptors.
There is a wealth of evidence demonstrating the eﬃcacy
and tolerability of clozapine in PD, but its use is limited
by the need of weekly blood testing for the initial 6
months of treatment [57]. A more practical alternative is
represented by quetiapine. Unlike clozapine, quetiapine does
not require monitoring of blood cell counts and it is eﬀective
in suppressing hallucinations and psychosis in the majorityParkinson’s Disease 5
of patients at relatively low doses, ranging from 12.5mg to
100mg.
Mainsideeﬀectsofquetiapineandclozapinearesedation
and postural hypotension.
4.3. Depression and Anxiety. Depression aﬀects 40–60% of
patients with PD and appears to be a major determinant of
health-related quality of life in PD [58].
In some cases depression occurs during oﬀ periods; thus
controlling the on-oﬀ ﬂuctuation can improve depression.
Sedating antidepressants, like tricyclic (TCA), and more
activating antidepressants, like selective serotonin reuptake
inhibitors (SSRIs) and serotonin-norepinephrine reuptake
inhibitors (SNRIs), are useful but signiﬁcantly limited in
advanced patients by the ancticholinergic and orthostatic
negative eﬀects. SSRIs are also contraindicated in patients
receiving slelegiline, because of the potential drug-drug
interation leading to “serotonin syndrome”.
S-Adenosyl-methionine (SAMe), a natural molecule
present in all eucaryotic cells that participates as methyl
group donor to a number of metabolic events, is reported
to have an eﬀective antidepressant eﬀects [59], without
worsening of Parkinsonism [60].
Anxiety often occurs during “oﬀ” periods and improves
with better control of motor symptoms but can be a major
source of distress for patients even during “on” state.
Low doses of benzodiazepines are eﬀective when anxiety
is persistent and debilitating but may cause amnesia and
confusion in advanced patients and are a risk factor for falls.
4.4. Sleep Disorders. Sleep disorders occur in almost all
patients with advanced PD, and they consist of sleep frag-
mentation, REM sleep behavior disorders (RBDs), excessive
daytime sleepiness, and altered sleep-wake cycle.
Sleep fragmentation can be caused by diﬃculty turning
in bed or nocturnal dystonia and can be ameliorated with
controlled-release levodopa. Increased nocturnal urinary
frequency can also aﬀect sleep and can be controlled by
reducing the amount of liquids in the evening, when
anticholinergic drugs are contraindicated.
RBD is a disruption of the normal REM sleep cycle,
in which the paralysis that normally occurs during REM
sleep is incomplete or absent, making the patient “act out”
their dreams, that usually are vivid, intense, and violent.
Dream-enacting behaviors can be complex, including talk-
ing, yelling, punching, kicking, jumping from bed, and
grabbing, with great distress for the patient and bed partner.
RBD also prevents physiological nocturnal restoration of
dopamine reseverve in cells, with worsening of parkinsonian
symptoms. RBD improves when dopaminergic medications
are reduced at bedtime. When RBD persists, low doses of
clonazepam are eﬀective and should be considered.
Modaﬁnil, a wake promoting agent approved for nar-
colepsy, is eﬀective in ameliorating daytime sleepiness
induced by dopamine-agonists without signiﬁcant side
eﬀects [61] and can be helpful in ameliorating alertness in
advanced PD.
4.5. Autonomic Dysfunction
4.5.1. Orthostatic Hypothension (OH). OH is deﬁned as
a fall in systolic blood pressure below 20mmHg and I
diastolic pressure below 10mmHg within 3minutes of
standing. Orthostatic intolerance related to OH results from
a reduction of cerebral perfusion when upright and presents
inseverecaseswithlightheadednessorsyncope,exposingthe
patient to high risk of fall.
Careful education of patients and caregivers on factors
that can trigger the OH symptoms, like avoiding rapid
changes of position or straining during micturition or
defecation, is essential in the management of OH.
Fluid intake, particularly in the morning, should be
maintained at around 2L of water daily and at least 8g
of sodium chloride is recommended to ensure adequate
hydration [62].
Antihypertensive therapy, when present, should be
reconsidered and eventually discontinued. Thromboembolic
elastic stocking and abdominal binders can be helpful and
should be encouraged.
When OH becomes more severe, it is necessary to start
pharamchological agents such as plasma volume expander,
like ﬂudrocortison, and vasoactive agents, like midodrine.
4.5.2. Dysphagia, Nutrition, and Hydration. Severe dyspha-
gia occurs frequently at late stage of disease causing weight
loss, malnutrition, dehydration, and signiﬁcantly increasing
the risk of inducing aspiration pneumonia and death.
In order to make the swallow safer and more eﬀec-
tive swallowing maneuvers, like the supraglottic swallow
maneuver, the super supraglottic swallow maneuver, the
Mendelsohn maneuver, and the eﬀortful swallow maneuver,
should be taught to patients.
Dysphagia for ﬂuid can be controlled adding thickening
agents, or thickeners, to liquids, increasing their viscosity
without substantially modifying their other properties, such
as taste. They provide body, increase stability, and improve
suspension of added ingredients. Some thickening agents
are gelling agents, forming a gel that can be swallowed by
patients signiﬁcantly reducing the risk of chocking.
When dysphagia becomes more severe, PEG should be
considered. In this phase PEG could be a useful solution to
guarantee to patients’ adequate food and ﬂuid intake as well
as dopaminergic therapy through infusion.
4.5.3.GenitourinaryandElimination. Constipationisacom-
mon and early manifestation of PD but in late stage
can become particularly severe due to the combination of
anti-PD medications, slowed intestinal motility, immobility,
and dehydration. Constipation should be well managed in
order to avoid bowel occlusion and in order to ensure
proper absorption of L-dopa and other medications. Dietary
supplementation of ﬁbers that stimulate intestinal motility
should be encouraged as well as increased ﬂuid intake.
A conservative therapeutic option is administration of
macrogol (polyethylene glycol), which can lead to marked
improvement [63].6 Parkinson’s Disease
Many late-stage PD patients face urinary problems such
as urgency or frequency or stress incontinence, which can
cause anxiety and feelings of social isolation. Overactive
bladder is the result of loss of normal inhibition by the
basal ganglia and the frontal cortex to the sacral spinal cord
[64]. Anticholinergics are commonly used to inhibit the
overactive bladder, although their use should be discouraged
in late-stage patients due to cognitive and other central
anticholinergic adverse eﬀects [65]. Newer generation of
peripheral anticholinergics, like trospium, is better tolerated
and can be used sometimes even in advanced patients.
Recently, botulinum toxin injections in the detrusor muscle
have demonstrated marked eﬃcacy in reducing the urinary
frequency with no side eﬀects [66].
Reduced mobility and diﬃculty toileting often lead to
the use of urinary pads or catheters at end stage of disease,
exposing the patients to high risk of urinary dangerous
infections when hygienic measures are not appropriate.
5. Supportive Care
Supportive care in advanced PD patients should include
physical and rehabilitative therapy, occupational therapy,
speechtherapy,social work,and nursing care.These careser-
vices could greatly beneﬁt late-stage patients by prolonging
independency in the ADL and reducing complications like
pain, decubiti, and falls.
5.1. Mobility. Full mobility should be encouraged and
maintained as long as possible. Occupational and physical
therapy should be encouraged whenever possible. Individual
rehabilitative therapy sessions should be encouraged two to
three times weekly for 30- to 40-minute durations even at
late-stage when the patient is able to safely ambulate. Falls
are perhaps the greatest concern for late stage PD patients
who are still mobile, and patients should be discouraged
to stand or walk without assistance at very late stage of
disease.Ifpatientsarebedridden,residualmobilityshouldbe
maintained through active and passive movement exercises,
frequentposition changes,and breathing exercises toprevent
complications associated with being bedridden, such as
decubitus, contracture, pain, and pneumonia [67].
5.2. Nutrition, Hydration, and Genitourinary Care. Malnu-
trition is a common problem in advanced PD patients. It
is caused by diﬃculty feeding, altered satiety mechanism,
diminished gastric and intestinal motility, inactivity, lack of
appetite, dysphagia, and metabolic syndrome. In patients
still able to eat independently, meal and portion sizes
should be monitored in order to provide suﬃcient nutrition.
Any eﬀort, including compensatory strategies, should be
considered to delay the PEG placement. Adequate hydration
is another concern for late-stage PD patients, since even
mild temperature change can lead to relative dehydration
and exacerbate confusion and OH and cause syncope. Many
patients become embarrassed when eating or drinking,
and nursing assistance, can assure adequate nutrition and
hydration through a nonjudgmental caregiver that assist
patients with the administration of meals.
5.3. Communication. Diﬃculty with speech with severe
dysarthria, hypophonia, tachylalia, and freezing of speech
is another problem associated with late-stage PD and leads
to signiﬁcant source of frustration for patients and families.
Speech therapy should be encouraged whenever possible.
TheLeeSilvermanVoicetreatmenthasbeenshown,clinically
and scientiﬁcally, to be a powerful method of improving
speech and related functions such as swallowing and facial
expression in PD, with documented Improvement in vocal
loudness, voice quality, prosody, and speech articulation,
sustained at 1-year and 2-year follow-ups [68]. Simpliﬁed
and codiﬁed communications (like asking yes/no questions,
or by using alphabet boards or speaking dictionaries) can
become the only way of eﬀective communication [69]a n d
should be considered.
6. Endof LifeCare
When patients with advanced PD encounter a medical
illness requiring an extended rehabilitation stay, they are
often transferred to subacute rehabilitation facilities with
no expertise in treating Parkinson’s disease. These transfers
often lead to an inevitable decline due to worsening of
dementia, psychosis, and social withdrawal. Nursing home
placement should be delayed as long as possible, because of
thewell-knownriskofreducedsurvival.Asdeathapproaches
for late-stage PD patients, it is important to provide them
with the best care possible in a passionate environment.
Many patients choose to do this through hospice care.
Support to families, through social work and psychological
counseling, should be oﬀered at this time.
7. Conclusion
The management of end-stage PD challenges clinicians,
patients, and families in many ways.
The main goal should be to maintain acceptable levels
of functioning through careful balance not limited to drug
management, but including strong and supportive services.
Many patients with advanced PD, in fact, beneﬁt from
a more intensive intervention to address the complexity of
the disease. Medication management can become arduous
with on/oﬀ ﬂuctuations and dyskinesias, frequent falls,
constipation, blood pressure instability, cardiac problems,
and other medical complications of PD developing and
becoming more severe as the disease progresses. The pro-
cess is further complicated when speech is aﬀected, and
swallowing becomes diﬃcult with malnutrition and risk of
developing aspiration pneumonia. Psychological problems
often accompany these later stages of the disease, including
anxiety, depression, and insomnia. Cognitive problems and
hallucinations also are prominent.
There comes a time when it becomes too diﬃcult
to manage all these complexities at home. Patients and
caregivers become overwhelmed, often with unnecessaryParkinson’s Disease 7
catastrophic consequences. Institutionalization typically fol-
lows the dramatic period of declining health and diminished
ability to cope. For most persons with advanced PD the
quality and dignity of a life at home are much superior to
whattheycaneverexpectinanursinghome.Awell-designed
interdisciplinary intervention can, in most cases, resolve
many problems and render the care of patients much more
manageable at home. Unfortunately, medical facilities are
unprepared to accommodate the needs of the neurologically
frail and complex PD patients.
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